Lopinavir/ritonavir sprinkle formulation - Cipla

Drug Profile

Lopinavir/ritonavir sprinkle formulation - Cipla

Alternative Names: Lopimune Sprinkles; Lopinavir/ritonavir mini-melt tablets formulation; Lopinavir/ritonavir oral pellets; Ritonavir/lopinavir

Latest Information Update: 07 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cipla
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation
  • Class Amides; Antiretrovirals; Pyrimidinones; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections
  • No development reported HIV infections

Most Recent Events

  • 01 Dec 2015 Phase-III clinical trials in HIV-1 infections (In children) in Kenya (PO)
  • 03 Jun 2015 Cipla collaborates with University College London for development of sprinkle formulation of lopinavir/ritonavir for HIV-1 infections before June 2015
  • 28 May 2015 Cipla has patent pending for Lopinavir and ritonavir sprinkles formulation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top